



RESVERLOGIX (TSX:RVX) IS A LATE-STAGE BIOTECHNOLOGY COMPANY WITH A NOVEL EPIGENETIC APPROACH TO REDUCING THE INCIDENCE OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN HIGH-RISK CARDIOVASCULAR PATIENTS. LEAD DRUG APABETALONE IS FULLY ENROLLED IN A PHASE 3 CLINICAL TRIAL CALLED BETONMACE.

Resverlogix is developing safe, affordable, first-in-class epigenetic therapeutics for people with heart disease, diabetes, chronic kidney disease and other life-threatening illnesses. Lead drug candidate **apabetalone** is in a fully enrolled **Phase 3 clinical trial, BETonMACE**.



MULTI-MODAL PATHWAY MECHANISM

Apabetalone, a bromodomain extra-terminal (BET) protein inhibitor regulates the expression of genes and restores the function of pathways underlying the pathogenesis of cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease.




✉ : ir@resverlogix.com
 ☎ : 403.254.9252
 🌐 : www.resverlogix.com
 🐦 : @Resverlogix_RVX



TSX:
RVX

CHROMOSOME CHROMATIN FIBRE NUCLEOSOME



EPIGENETICS

A mechanism for regulating gene activity independent of DNA sequence that determines which genes are turned on or off:

- o in a particular cell type
- o in different disease states
- o in response to a physiological stimulus


COPYRIGHT © 2012 - RICHARD E. BALLERMANN

Epigenetics


While most people are familiar with the inheritance of genes via DNA from one generation to the next, the activity of these genes is actually determined by epigenetics, which literally means "on top of" genetics. DNA is considered the hardware of the human body, while epigenetics can be referred to as the software. DNA contains the code that tells our cells what to do, and this coded message is the same in every cell and does not change with time. However, our cells do not behave in the exact same way across time, particularly when disease is involved. Epigenetic changes to the DNA allow the message in the genes to be turned up or down like a dimmer switch, telling the cells which products to make more, or less of. During this process the DNA is not altered. The epigenetic control over the genetic message in the DNA underlies many diseases, and for this reason, epigenetics has become an exciting forefront for the discovery of new medicines.

APABETALONE (RVX-208) CLINICAL TRIAL HISTORY

Completed Trials



Current and Planned Trials



- Phase 3 BETonMACE trial commenced Q4/15 for high-risk CVD patients with type 2 diabetes mellitus and low HDL.
- BETonMACE is fully enrolled.
- Primary endpoint: time to first occurrence of Major Adverse Cardiac Events (MACE).
- Based on mechanistic data, we believe apabetalone treatment, or select BET inhibition, attenuates the pathological process that contributes to disease initiation and progression.

News Highlights

April 1, 2019 - RVX Announces \$15.1 Million of Private Placements.

April 1, 2019 - RVX Cognition Substudy of BETonMACE Phase 3 CVD Trial Presented at the International Conference on Alzheimer's and Parkinson's Diseases.

March 27, 2019 - RVX Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 BETonMACE Study of Apabetalone.

Analysts

Roth Capital Partners: Jotin Marango, MD, PhD.
Van Leeuwenhoeck Research: Marcel Wijma, MSc.
Zacks: John Vandermosten, CFA.

Future Events

April 6-12, 2019 - Gordon Research Conference, Florence, Italy.
May 14-16, 2019 - Vascular Discovery Scientific Sessions 2019, Boston, MA.
May 26-29, 2019 - European Atherosclerosis Society (EAS) 2019, Maastricht, NL
May 26-31, 2019 - Gordon Research Conference, Hong Kong.

Financial Profile

- Shares O/S (MM): ~200
- Share Price: \$3.28
- Market Cap (MM): ~\$667
- 52 week low/high: \$1.11/\$4.31
- Total Cash Raised (MM): ~\$484.2

Notes:

*As at 3-APRIL-2019

*All figures in CAD\$